Moderna (MRNA) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US60770K1079

(NASDAQ:MRNA Stock) Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Moderna (MRNA) - Stock Price & Dividends

MRNA Stock Overview

Market Cap in USD 38,529m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2018-12-07

MRNA Stock Ratings

Fundamental -5.95
Dividend -
Growth 5y 3.30
Rel. Performance vs Sector -7.23
Analysts 3.76
Fair Price Total Ret. 96.25
Fair Price DCF -

MRNA Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

MRNA Growth Ratios

Growth 12m -44.62%
Growth Correlation 12m -68%
Growth Correlation 3m 34%
CAGR 5y 32.19%
CAGR / Mean Drawdown 0.73
Sharpe Ratio 12m -1.04
Alpha vs SP500 12m -70.67
Beta vs SP500 5y weekly 0.97
CAPM 7.92%
Average Daily Range 2m 4.70%
Regime Oscillator 35.76
Volatility GJR Garch 1y 59.85%
Price / SMA 50 -9.26%
Price / SMA 200 -15.63%
Current Volume 3752.7k
Average Volume 20d 3501.7k

External Links for MRNA Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of MRNA stocks?
As of February 22, 2024, the stock is trading at USD 87.59 with a total of 3,752,700 shares traded.
Over the past week, the price has changed by +1.91%, over one month by -12.15%, over three months by +13.55% and over the past year by -45.29%.
Why is MRNA stock down?
Check with which Index or Commodity MRNA has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return MRNA Return S&P 500
1 Month -12.15% 2.85%
3 Months 13.55% 10.14%
12 Months -45.29% 26.48%
What is the forecast for MRNA stock price target?
According to ValueRays Forecast Model, MRNA Moderna will be worth about 105.3 in February 2025. The stock is currently trading at 87.59. This means that the stock has a potential upside of +20.22%.
Issuer Forecast Upside
Wallstreet Target Price 129.3 47.6%
Analysts Target Price 167.7 91.4%
ValueRay Target Price 105.3 20.2%